Overview

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies

Status:
Recruiting
Trial end date:
2026-12-17
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-cell malignancies (types of non-Hodgkin's lymphoma [NHL]).
Phase:
Phase 2
Details
Lead Sponsor:
Genentech, Inc.